Last edition
News about "Zydus Baddi Facility"
Zydus Secures Final USFDA Approval for Diltiazem Hydrochloride Tablets
Zydus Lifesciences has received final USFDA approval to market Diltiazem Hydrochloride Tablets in 30 mg, 60 mg, 90 mg, and 120 mg dosages for the treatment of chronic stable angina and angina due to coronary artery spasm in the US.
Zydus Baddi Facility | 11/08/2025 | By Mrinmoy Dey
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members